Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.35
Bid: 8.00
Ask: 8.70
Change: 0.20 (2.45%)
Spread: 0.70 (8.75%)
Open: 8.25
High: 8.35
Low: 8.25
Prev. Close: 8.15
TEK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Takeover Code Form 8.3 - Belluscura plc

16 Oct 2023 07:00

RNS Number : 1479Q
Tekcapital plc
16 October 2023

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Full name of discloser:

TEKCAPITAL PLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Belluscura plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

16 October 2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

1p Ordinary

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

15,138,767

11.01%

0

0

(2) Cash-settled derivatives:

0

0

0

0

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0

0

0

TOTAL:

15,138,767

11.01%

0

0

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

16/10/2023

Contact name:

Max Inglis

Telephone number*:

+44 (0)7779 306653

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RETFLFEVIILELIV
Date   Source Headline
26th Apr 20247:00 amRNSInnovative Eyewear Canadian Partnership
25th Apr 20247:00 amRNSInnovative Eyewear Patent Filings
18th Apr 20247:00 amRNSInnovative Eyewear Signs Brand Ambassador
17th Apr 20247:00 amRNSInnovative Eyewear Distribution Partnership
9th Apr 20247:00 amRNSPortfolio Company Update : Guident Ltd
5th Apr 20247:00 amRNSPortfolio Company Update : Guident Ltd
28th Mar 202410:20 amRNSNotification of Major Holdings
7th Mar 202411:15 amRNSNotification of Major Holdings
6th Mar 20247:00 amRNSIntellectual Property Update
29th Feb 20247:51 amRNSFundraising of £2.0 million
19th Feb 20247:00 amRNSPortfolio Company Update : Guident Ltd
15th Feb 202410:31 amRNSNotification of Major Holdings
15th Feb 20247:00 amRNSGuident Expands its Strategic Partnership
13th Feb 20242:24 pmRNSNotification of Major Holdings
1st Feb 20247:15 amRNSMicroSalt Admission to AIM First Day of Dealings
1st Feb 20247:01 amRNSNotice of Presentation on Investor Meet Company
24th Jan 20247:00 amRNSBellescura Plc - Disposal of Shares
12th Jan 20244:31 pmRNSLoan Agreement with Innovative Eyewear Inc
11th Jan 20247:00 amRNSInnovative Eyewear Patent Applications
9th Jan 20247:00 amRNSMicroSalt expand Placement Low Sodium Salt Shakers
22nd Dec 20237:00 amRNSAnnual Corporate & Strategy Update
14th Dec 20237:00 amRNSInnovative Eyewear Appoints Brand Ambassador
13th Dec 20237:00 amRNSInnovative Eyewear Update for Android ChatGPT App
12th Dec 20237:00 amRNSInnovative Eyewear,Inc. Global Licensing Agreement
17th Nov 20237:00 amRNSInnovative Eyewear Launches Upgraded Charging Dock
16th Nov 202312:12 pmRNSForm 8.3 - Belluscura PLC
1st Nov 20237:00 amRNSMicroSalt placement SaltMe! Crisps in MR Williams
19th Oct 20237:00 amRNSMicroSalt placement of SaltMe Low Sodium Crisps
17th Oct 20237:00 amRNSInnovative Eyewear Launches New Collection
16th Oct 20237:00 amRNSTakeover Code Form 8.3 - Belluscura plc
5th Oct 20237:00 amRNSBelluscura Update
5th Oct 20237:00 amRNSNotification of Major Holdings
3rd Oct 20238:00 amRNSMicroSalt Primary Bid Offer Files Schedule One
29th Sep 20238:00 amRNSHalf Yearly Report for period ending 30 June 2023
19th Sep 20237:00 amRNSMicroSalt Partnership with Weijohn Farms Group
13th Sep 20234:15 pmRNSNotification of Major Holdings
11th Sep 20237:00 amRNSInnovative Eyewear Announces Patent Filing
7th Sep 20237:00 amRNSMicroSalt files New Patent to Improve Baked Goods
6th Sep 20237:00 amRNSGuident Update
24th Aug 20237:00 amRNSPortfolio Company Update - Guident
17th Aug 20237:00 amRNSPortfolio Companies Update
14th Aug 20237:00 amRNSLucyd ChatGPT App Update for Smart Eyewear
1st Aug 20237:00 amRNSInnovative Eyewear Launches Lucyd Blueshift Lens
31st Jul 20237:00 amRNSMicroSalt commercial orders for SaltMe Crisps
30th Jun 20237:00 amRNSInnovative Eyewear Miami Fashion Week
28th Jun 20237:00 amRNSInnovative Eyewear Partnership with PRIVATO
26th Jun 20237:00 amRNSMicroSalt Expands U.S. Retail Network
22nd Jun 20231:38 pmRNSResults of Annual General Meeting
22nd Jun 20231:27 pmRNSInnovative Eyewear US$ 4.7Million Public Offering
20th Jun 20237:00 amRNSInnovative Eyewear Licensing Agreement for Reebok

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.